"Umuti w'igitangaza wo kugabanya ibiro" uri hafi kwinjira mu Bushinwa!Novo Nordisk Ubushinwa bwemeza verisiyo yo kugabanya ibiro bya Semaglutide izemezwa muri uyu mwaka

"Umuti w'igitangaza wo kugabanya ibiro" uri hafi kwinjira mu Bushinwa!Novo Nordisk Ubushinwa bwemeza verisiyo yo kugabanya ibiro bya Semaglutide izemezwa muri uyu mwaka
Ku ya 8 Werurwe, amakuru avuga ko Novo Nordisk ateganijwe kugabanya ibiro bya Semaglutide Wegovy azemerwa mu Bushinwa muri uyu mwaka, ibicuruzwa bizaba intangiriro y’abarwayi baterwa inkunga, kandi hari umubare w’abarwayi.Ni muri urwo rwego, Novo Nordisk Ubushinwa bwemeje aya makuru yavuzwe haruguru ku munyamakuru ugenda wiyongera, ati: "dutegereje kwemezwa muri uyu mwaka, vuba bishoboka kugira ngo bigirire akamaro abarwayi bafite umubyibuho ukabije mu Bushinwa."

Wegovy ni izina ry'ubucuruzi bw'icyongereza ry'umuti wa GLP-1 Semaglutide wakozwe na Novo Nordisk kugira ngo ugaragaze ko wagabanutse ibiro, byemejwe nk'umuti ugabanya ibiro muri Kamena 2021 muri Amerika.Umuyobozi mukuru wa Tesla, Musk yigeze kuvuga ku mbuga nkoranyambaga ko yakoresheje ibiyobyabwenge mu kugabanya ibiro, kandi byigeze gushakishwa nk "" ibiyobyabwenge by’igitangaza byo kugabanya ibiro ".

Mu Bushinwa, inshinge za Semaglutide n’ibiyobyabwenge byo mu kanwa byemewe gusa ku bimenyetso bya diyabete, muri byo hakaba haterwa inshinge ya simethicone izemezwa ku isoko mu Bushinwa muri Mata 2021, hanyuma ikinjira mu gitabo cy’ubwishingizi bw’ubuzima mu 2022;umunwa Semaglutide yemejwe muri Mutarama uyu mwaka, kandi ibaye imiti ya mbere yo mu kanwa GLP-1 yemewe yo kwamamaza mu Bushinwa.

Nkuhagarariye ibiyobyabwenge bya GLP-1, Semaglutide yatsinze ubucuruzi.Raporo y’imari ya 2023 ya Novo Nordisk yerekanye ko igurishwa rya Wegovy ryazamutseho 406% kugeza kuri miliyari 4,6 z'amadolari, rikaba ryayoboye isi yose GLP-1.Kubera iyo mpamvu, ibigo byinshi by’ibiyobyabwenge byo mu gihugu byerekana imiterere ya Semaglutide biosimilar iteza imbere ibiyobyabwenge, ariko ibyinshi biri mubyiciro byambere byubuvuzi, nka Liju Group (000513), Han Yu Pharmaceutical (300199) nandi masosiyete menshi yibiyobyabwenge mbere yatangaje ko Semaglutide yikigo inshinge zemejwe gukora ibizamini byamavuriro kubimenyetso bijyanye no gucunga ibiro.

Twabibutsa ko, hamwe na Novo Nordisk izwi nka "GLP-1 duo" LLY nayo irimo guteza imbere urutonde rw’imiti igabanya ibiro bya GLP-1 Tirzepatide mu Bushinwa, bikaba biteganijwe kandi ko izemezwa mu gihugu.2023 Kanama, LLY Ubushinwa bwatangaje ko, nk'uko bigaragara ku rubuga rwemewe rw'ikigo gishinzwe gusuzuma ibiyobyabwenge mu kigo cya Leta gishinzwe ibiyobyabwenge.Gusaba kwiyandikisha mu gutera inshinge za Tirzepatide hagamijwe kunoza imicungire yigihe kirekire ku barwayi bafite umubyibuho ukabije ufite umubyibuho ukabije cyangwa byibuze byibuze kimwe kijyanye n’uburemere hashingiwe ku ndyo ya calorie nkeya no kongera imyitozo byemewe ku mugaragaro.

Indwara ya diyabete kuri Tirzepatide yemejwe muri Amerika muri Gicurasi 2022, kandi uyu muti watanze Lilly miliyoni 483 z'amadolari y’Amerika mu 2022. amezi abiri atarenga miliyoni 176 yinjiza.

Hamwe n’imiti ya Novo Nordisk na LLY GLP-1 biteganijwe ko izemezwa kugira ngo hagabanuke ibiro mu Bushinwa, amarushanwa hagati ya Novo Nordisk na LLY ku murongo wa GLP-1 arashobora gutangira vuba mu Bushinwa.